Neovasc (NASDAQ: NVCN) and Boston Scientific Corporation (NYSE:BSX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.

Valuation and Earnings

This table compares Neovasc and Boston Scientific Corporation’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Neovasc $8.58 million 12.97 -$23.14 million ($0.14) -10.07
Boston Scientific Corporation $8.71 billion 4.66 $2.31 billion $0.58 51.05

Boston Scientific Corporation has higher revenue and earnings than Neovasc. Neovasc is trading at a lower price-to-earnings ratio than Boston Scientific Corporation, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

19.6% of Neovasc shares are held by institutional investors. Comparatively, 90.3% of Boston Scientific Corporation shares are held by institutional investors. 0.7% of Boston Scientific Corporation shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Neovasc and Boston Scientific Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neovasc -68.34% -58.08% 23.23%
Boston Scientific Corporation 9.04% 23.62% 9.01%

Volatility & Risk

Neovasc has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Boston Scientific Corporation has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Neovasc and Boston Scientific Corporation, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neovasc 0 0 3 0 3.00
Boston Scientific Corporation 0 4 12 0 2.75

Neovasc presently has a consensus target price of $6.33, suggesting a potential upside of 349.17%. Boston Scientific Corporation has a consensus target price of $30.58, suggesting a potential upside of 3.27%. Given Neovasc’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Neovasc is more favorable than Boston Scientific Corporation.

Summary

Boston Scientific Corporation beats Neovasc on 9 of the 13 factors compared between the two stocks.

Neovasc Company Profile

Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Receive News & Ratings for Neovasc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.